- Home
- EQNR vs ZTS Comparison
EQNR vs ZTS Comparison
Compare EQNR & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQNR
- ZTS
- Stock Information
- Founded
- EQNR 1972
- ZTS 1952
- Country
- EQNR Norway
- ZTS United States
- Employees
- EQNR N/A
- ZTS N/A
- Industry
- EQNR Integrated oil Companies
- ZTS Biotechnology: Pharmaceutical Preparations
- Sector
- EQNR Energy
- ZTS Health Care
- Exchange
- EQNR Nasdaq
- ZTS Nasdaq
- Market Cap
- EQNR 69.9B
- ZTS 80.4B
- IPO Year
- EQNR N/A
- ZTS 2013
- Fundamental
- Price
- EQNR $24.56
- ZTS $167.47
- Analyst Decision
- EQNR Buy
- ZTS Strong Buy
- Analyst Count
- EQNR 6
- ZTS 8
- Target Price
- EQNR $29.45
- ZTS $215.38
- AVG Volume (30 Days)
- EQNR 2.8M
- ZTS 2.7M
- Earning Date
- EQNR 02-05-2025
- ZTS 02-13-2025
- Dividend Yield
- EQNR 5.49%
- ZTS 1.03%
- EPS Growth
- EQNR N/A
- ZTS 8.38
- EPS
- EQNR 3.27
- ZTS 5.32
- Revenue
- EQNR $104,810,000,000.00
- ZTS $9,152,000,000.00
- Revenue This Year
- EQNR N/A
- ZTS $9.48
- Revenue Next Year
- EQNR N/A
- ZTS $4.87
- P/E Ratio
- EQNR $7.03
- ZTS $31.51
- Revenue Growth
- EQNR N/A
- ZTS 9.33
- 52 Week Low
- EQNR $21.85
- ZTS $144.80
- 52 Week High
- EQNR $29.49
- ZTS $200.53
- Technical
- Relative Strength Index (RSI)
- EQNR 51.37
- ZTS 49.25
- Support Level
- EQNR $25.35
- ZTS $161.58
- Resistance Level
- EQNR $25.79
- ZTS $169.78
- Average True Range (ATR)
- EQNR 0.42
- ZTS 3.58
- MACD
- EQNR 0.03
- ZTS 0.87
- Stochastic Oscillator
- EQNR 47.92
- ZTS 74.86
About EQNR Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2023 (53% liquids) and ended 2023 with 5.2 billion barrels of proven reserves (49% liquids). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.